Our finding that DMAb suppression of DPP4 may contribute to improved glucose homeostasis in patients with type 2 diabetes also provides a strong rationale for future studies examining the role of RANKL inhibition in simultaneously treating osteoporosis and diabetes, two common age-related co-morbidities. The gene discussed is DPP4; the disease is osteoporosis.